Contact Information: Public Relations: 678-881-0002 Ext. 704 e-mail:
ALRT Health-E-Connect Diabetes Management System Used in Clinical Trial to Determine Adherence of Prescribed Self-Testing of Blood Sugar and Its Effects on Type 2 Diabetes
| Source: ALR Technologies Inc.
ATLANTA GA--(Marketwire - January 12, 2009) - ALR Technologies Inc. (OTCBB : ALRT ) announces
the funding for a clinical trial (the Trial) sponsored by Endocrine
Research Society (ERS) of Vancouver, Canada. The objective of this trial is
to determine the effectiveness of ALRT's diabetes compliance system vs.
standard regimen on increasing patient compliance with prescribed
self-testing of blood sugar in Type 2 diabetics.
Currently, industry data indicates that only 14% of prescribed self-testing
of blood sugar is actually performed. Results from a pilot project
reported by ALRT in 2008 showed self-testing increased from 1.4 times per
day to 3.1 times per day and A1c decreased from 7.6 to 6.7
(See: http://www.alrt.com/news_releases/news081208.html)
Adherent self-testing of blood sugar as prescribed is necessary for
effective self-management of diabetes by patients. Effective
self-management lowers A1c levels and will improve containment of
complications due to diabetes.
Patients in the Trial will be using ALRT's Health-E-Connect web based
communication system to upload their time stamped blood sugar data direct
from glucometers. The data is securely reported to designated health
professionals for review. Adjustments to therapies as required in between
visits to the clinic can be efficiently dispensed by authorized health
professionals.
Abbott Diabetes Care is providing diabetes testing supplies for the Trial.
Details of the trial are available at:
http://www.clinicaltrials.gov/ct2/show/NCT00814190?term=NCT00814190&rank=1
About ERS, Endocrine Research Society, Vancouver, Canada
The Society conducts research on new drugs and procedures. It organizes an
annual diabetes directors' seminar (a conference for the medical directors
of diabetes centers of B.C.), the annual Bill Vlahos Memorial Lecture and
annual B.C. Endocrine Days (a conference on Endocrinology for general
practitioners) and Annual Kelowna Endocrine Days (A conference on
Endocrinology for specialists). The Society maintains a database to
evaluate patient outcomes. Additional information on ERS or the clinical
trial contact: Adel Mazanderani at 604-602-1011; email:
amazanderane.ers@shaw.ca
About ALR Technologies Inc.
The ALRT Health-E-Connect Disease Management System is designed to enhance
compliance of prescribed therapies and report diagnostic data from a number
of devices to health professionals for monitoring of patients. The System
facilitates cost effective continued oversight of patients by authorized
health professionals in between visits to the clinic. More information on
ALR Technologies and its products can be found at http://www.alrt.com.
Public Relations: 678-881-0002 Ext. 704 e-mail: info@alrt.com
This release contains certain "forward-looking statements" relating to ALR
Technologies' business, and these statements reflect the current views of
ALR Technologies with respect to future events and are subject to certain
risks, uncertainties and assumptions. When used, the words "estimate,"
"expect," "anticipate," "believe" and similar expressions are intended to
identify such forward-looking statements. There are many factors that
could cause the actual results, performance or achievements of ALR
Technologies and its products to be materially different from any future
results, performances or achievements that may be expressed or implied by
such forward-looking statements. Further management discussions of risks
and uncertainties can be found in the company's quarterly filings with the
Securities Exchange Commission.